Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 8/20 | 0.44 |
| ▸ | MMP13 | P45452 | 5/20 | 0.44 |
| ▸ | MMP9 | P14780 | 9/20 | 0.43 |
| ▸ | MMP8 | P22894 | 5/20 | 0.43 |
| ▸ | MMP1 | P03956 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | MMP3 | P08254 | 3/20 | 0.37 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.36 |
| ▸ | MMP7 | P09237 | 1/20 | 0.36 |
| ▸ | BMP1 | P13497 | 2/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7123675 | 1.00 | MMP2 (0.44) | MMP2MMP13MMP9MMP8MMP1 | |
| SCHEMBL7125674 | 0.87 | MMP9 (0.47) | MMP2MMP13MMP9MMP8MMP1 | |
| SCHEMBL7125684 | 0.87 | MMP9 (0.47) | MMP2MMP13MMP9MMP8MMP1 | |
| SCHEMBL7115876 | 0.85 | MMP2 (0.40) | MMP2MMP13MMP9MMP8NAMPT | |
| SCHEMBL7115873 | 0.85 | MMP2 (0.40) | MMP2MMP13MMP9MMP8NAMPT | |
| SCHEMBL7115880 | 0.85 | MMP2 (0.40) | MMP2MMP13MMP9MMP8NAMPT | |
| SCHEMBL7123526 | 0.81 | MMP2 (0.42) | MMP2MMP13MMP9MMP8MMP1 | |
| SCHEMBL7123531 | 0.81 | MMP2 (0.42) | MMP2MMP13MMP9MMP8MMP1 | |
| SCHEMBL7545020 | 0.79 | GRM2 (0.40) | MMP2MMP9NAMPTADAMTS4 | |
| SCHEMBL7545000 | 0.79 | GRM2 (0.40) | MMP2MMP9NAMPTADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030134880-A1 | Novel cd23 inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134880-A1 | Novel cd23 inhibitors | CD2, CD22, CD40 | MMP2 1392/4885MMP13 335/4885MMP9 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.